APOL1 Variant Detection for Kidney Disease Risk Stratification
Solution Overview
Problem
Current methods fail to accurately determine predisposition to kidney diseases, particularly in African Americans, where genetic variants like those in the MYH9 gene have been associated with increased risk, but functional mutations remain unidentified, limiting effective prevention and treatment strategies.
Innovation Solution
Identifying APOL1 polypeptide variants with higher trypanolytic activity or specific nucleotide mutations in linkage disequilibrium with the S342G mutation, which indicate increased predisposition to kidney disease, allowing for personalized lifestyle changes and treatment regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If MYH9 gene variants are used to determine kidney disease predisposition, then risk identification is improved, but functional mutation identification fails
Solution Approach 1:
The patent uses APOL1 gene variants as an intermediary marker to identify kidney disease predisposition. Instead of directly detecting the functional MYH9 mutations which are difficult to identify, the invention detects APOL1 variants (specifically G1 G2 haplotype combinations) that are in linkage disequilibrium with the risk alleles, serving as a reliable proxy indicator for kidney disease susceptibility.
2Adaptability or versatility
If genetic testing for kidney disease risk is performed, then prevention strategy personalization is improved, but measurement accuracy for African American population is insufficient
Solution Approach 1:
The patent applies local quality by specifically addressing the genetic characteristics of the African American population. It identifies that APOL1 gene variants (G1 and G2 haplotypes) are particularly prevalent in this population and are strongly associated with kidney disease risk. The testing methodology is optimized for this specific population group, using population-specific haplotype frequencies and risk thresholds to achieve accurate risk stratification.
Data Source
AI summary
Provided are methods and kits for determining predisposition of a subject to develop a kidney disease, by identifying in a sample of the subject at least one APOL1 polypeptide variant which is characterized by a higher trypanolytic activity on Trypanosoma brucei rhodesiense as compared to the trypanolytic activity of wild type APOL1 polypeptide as set forth in SEQ ID NO:1 on the Trypanosoma brucei rhodesiense under identical assay conditions; or at least one APOL1 nucleotide mutation in the APLO1 genomic sequence set forth in SEQ ID NO:3, wherein the at least one nucleotide mutation or polypeptide variant being in linkage disequilibrium (LD) with the S342G mutation in the APOL1 polypeptide set forth in SEQ ID NO:1, wherein presence of the APOL1 polypeptide variant indicates increased predisposition of the subject to develop the kidney disease.